Guys. We need to talk about this Hydroxychloroquine + Azithromycin thing. It is out of hand. It all stems from this study that came out today. The study design: Comparative viral eradication on day 6 between HCQ, HCQ + Azithro, and control (not treated) COVID-19 patients. pic.twitter.com/qFZXdTxTwI— Jason Pogue (@jpogue1) March 20, 2020
Guys. We need to talk about this Hydroxychloroquine + Azithromycin thing. It is out of hand. It all stems from this study that came out today. The study design: Comparative viral eradication on day 6 between HCQ, HCQ + Azithro, and control (not treated) COVID-19 patients. pic.twitter.com/qFZXdTxTwI
So to recap: 1) This study had a lower threshold for "negative" than most and used as less sensitive swab sample2) There were a decent number (23%) of total HCQ patients who were not eligible for analysis, but at least five could be considered failures.— Jason Pogue (@jpogue1) March 20, 2020
So to recap: 1) This study had a lower threshold for "negative" than most and used as less sensitive swab sample2) There were a decent number (23%) of total HCQ patients who were not eligible for analysis, but at least five could be considered failures.
2a) These failures could lessen the spread between HCQ and control2b) These failures would impact monotherapy vs combination therapy (unclear how as they are not described)3) When correcting for burden of disease/viral load, HCQ and HCQ + AZ look extremely similar— Jason Pogue (@jpogue1) March 20, 2020
2a) These failures could lessen the spread between HCQ and control2b) These failures would impact monotherapy vs combination therapy (unclear how as they are not described)3) When correcting for burden of disease/viral load, HCQ and HCQ + AZ look extremely similar
